13 results on '"Haberkorn, B.C.M."'
Search Results
2. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
- Author
-
van Loenhout, C.J., van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, B.E.E.M., van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P., Libourel, E.J., Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C., Heller, R., de Groot, J.W.B., Stigt, J.A., Nuij, V.J.A.A., Pitz, C.C.M., Slingerland, M., Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C. van 't, Aarts, M.J.B., van Putten, J.W.G., Youssef, M., Cirkel, G.A., Herder, G.J.M., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H.T., Claessens, N.J.M., Faber, L.M., Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H., Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M., van Lindert, A.S.R., van de Wouw, A.J., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P., de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne-Marie C., and van der Veldt, Astrid A.M.
- Published
- 2020
- Full Text
- View/download PDF
3. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
- Author
-
Bond, M.J.G., Bolhuis, K., Loosveld, O.J.L., Groot, J.W.B. de, Droogendijk, H., Helgason, H.H., Hendriks, M.P, Klaase, J.M., Kazemier, G., Liem, M.S.L., Rijken, A.M., Verhoef, C., Wilt, J.H.W. de, Jong, K.P. de, Gerhards, M.F., Amerongen, M.J. van, Engelbrecht, M.R.W., Lienden, K.P. van, Molenaar, I.Q., Valk, B. de, Haberkorn, B.C.M., Kerver, E.D., Erdkamp, F., Alphen, R.J. van, Mathijssen-van Stein, D., Komurcu, A., Lopez-Yurda, M., Swijnenburg, R.J., Punt, C.J.A., Bond, M.J.G., Bolhuis, K., Loosveld, O.J.L., Groot, J.W.B. de, Droogendijk, H., Helgason, H.H., Hendriks, M.P, Klaase, J.M., Kazemier, G., Liem, M.S.L., Rijken, A.M., Verhoef, C., Wilt, J.H.W. de, Jong, K.P. de, Gerhards, M.F., Amerongen, M.J. van, Engelbrecht, M.R.W., Lienden, K.P. van, Molenaar, I.Q., Valk, B. de, Haberkorn, B.C.M., Kerver, E.D., Erdkamp, F., Alphen, R.J. van, Mathijssen-van Stein, D., Komurcu, A., Lopez-Yurda, M., Swijnenburg, R.J., and Punt, C.J.A.
- Abstract
01 juli 2023, Item does not contain fulltext, BACKGROUND: Patients with initially unresectable colorectal cancer liver metastases might qualify for local treatment with curative intent after reducing the tumour size by induction systemic treatment. We aimed to compare the currently most active induction regimens. METHODS: In this open-label, multicentre, randomised, phase 3 study (CAIRO5), patients aged 18 years or older with histologically confirmed colorectal cancer, known RAS/BRAF(V600E) mutation status, WHO performance status of 0-1, and initially unresectable colorectal cancer liver metastases were enrolled at 46 Dutch and one Belgian secondary and tertiary centres. Resectability or unresectability of colorectal cancer liver metastases was assessed centrally by an expert panel of liver surgeons and radiologists, at baseline and every 2 months thereafter by predefined criteria. Randomisation was done centrally with the minimisation technique via a masked web-based allocation procedure. Patients with right-sided primary tumour site or RAS or BRAF(V600E) mutated tumours were randomly assigned (1:1) to receive FOLFOX or FOLFIRI plus bevacizumab (group A) or FOLFOXIRI plus bevacizumab (group B). Patients with left-sided and RAS and BRAF(V600E) wild-type tumours were randomly assigned (1:1) to receive FOLFOX or FOLFIRI plus bevacizumab (group C) or FOLFOX or FOLFIRI plus panitumumab (group D), every 14 days for up to 12 cycles. Patients were stratified by resectability of colorectal cancer liver metastases, serum lactate dehydrogenase concentration, choice of irinotecan versus oxaliplatin, and BRAF(V600E) mutation status (for groups A and B). Bevacizumab was administered intravenously at 5 mg/kg. Panitumumab was administered intravenously at 6 mg/kg. FOLFIRI consisted of intravenous infusion of irinotecan at 180 mg/m(2) with folinic acid at 400 mg/m(2), followed by bolus fluorouracil at 400 mg/m(2) intravenously, followed by continuous infusion of fluorouracil at 2400 mg/m(2). FOLFOX consisted of oxaliplatin at
- Published
- 2023
4. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients
- Author
-
Sijde, F. van der, Dik, W.A., Mustafa, D.A.M., Vietsch, E.E., Besselink, M.G., Debets, R., Koerkamp, B.G., Haberkorn, B.C.M., Homs, M.Y.V., Janssen, Q.P., Luelmo, S.A.C., Mekenkamp, L.J.M., Oostvogels, A.A.M., Nijenhuis, M.A.W.S.T., Wilmink, J.W., Eijck, C.H.J. van, Surgery, Immunology, Pathology, Medical Oncology, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Oncology, and CCA - Cancer biology and immunology
- Subjects
Interleukin-7 ,pancreatic cancer ,Immunology ,Interleukin-18 ,Leucovorin ,treatment response ,Irinotecan ,Oxaliplatin ,Pancreatic Neoplasms ,Interleukin 1 Receptor Antagonist Protein ,IL-1RA ,SDG 3 - Good Health and Well-being ,Antineoplastic Combined Chemotherapy Protocols ,cytokine ,Cytokines ,Humans ,biomarker ,Immunology and Allergy ,Fluorouracil ,Chemokine CCL4 ,Carcinoma, Pancreatic Ductal - Abstract
BackgroundBiomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response and with overall survival (OS).MethodsSerum samples were collected before start and after the first cycle of FOLFIRINOX from patients with PDAC (n=83) of all disease stages. Overall, 34 circulating cytokines were analyzed with a multiplex immunoassay. In addition, changes in peripheral blood immune cell counts were determined by flow cytometry to correlate with differences in cytokine levels. Chemotherapy response was determined by CT scans with the RECIST 1.1 criteria, as disease control (n=64) or progressive disease (n=19) within eight cycles of FOLFIRINOX.ResultsPatients with high serum IL-1RA concentrations after one cycle of chemotherapy were less likely to have tumor progression during FOLFIRINOX (OR 0.25,P=0.040). Increase of circulating IL-1RA concentrations correlated with increase of total, classical (CD14+CD16-), and non-classical monocytes (CD14-CD16+), and dendritic cells. In multivariable cox regression, including the variables chemotherapy response outcome and baseline CA19-9 level, serum concentrations of IL-7 (HR 2.14,P=0.010), IL-18 (HR 2.00,P=0.020), and MIP-1β (HR 0.51,P=0.025) after one cycle of FOLFIRINOX showed correlations with OS.ConclusionsCirculating IL-1RA, IL-7, IL-18, and MIP-1β concentrations are biomarkers associated with FOLFIRINOX response in PDAC patients, suggesting an important role for specific immune cells in chemotherapy response and PDAC progression. Cytokine-based treatment might improve patient outcome and should be evaluated in future studies.
- Published
- 2022
- Full Text
- View/download PDF
5. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
- Author
-
de Joode, Karlijn, primary, Tol, Jolien, additional, Hamberg, Paul, additional, Cloos, Marissa, additional, Kastelijn, Elisabeth A., additional, Borgers, Jessica S.W., additional, Nuij, Veerle J.A.A., additional, Klaver, Yarne, additional, Herder, Gerarda J.M., additional, Mutsaers, Pim G.N.J., additional, Dumoulin, Daphne W., additional, Oomen-de Hoop, Esther, additional, van Diemen, Nico G.J., additional, Libourel, Eduard J., additional, Geraedts, Erica J., additional, Bootsma, Gerben P., additional, van der Leest, Cor H., additional, Peerdeman, Anne L., additional, Herbschleb, Karin H., additional, Visser, Otto J., additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, de Vries, Elisabeth G.E., additional, Hendriks, Lizza E.L., additional, Beerepoot, Laurens V., additional, Westgeest, Hans M., additional, van den Berkmortel, Franchette W.P.J., additional, Haanen, John B.A.G., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, Becker-Commissaris, A., additional, Terheggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Strobbe, L., additional, Koekkoek, J.A.F., additional, Brocken, P., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, van 't Westeinde, S.C., additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, and van Geffen, W.H., additional
- Published
- 2022
- Full Text
- View/download PDF
6. LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
- Author
-
Groot Koerkamp, B., Janssen, Q.P., van Dam, J.L., Bonsing, B.A., Bos, H., Bosscha, K.P., Haberkorn, B.C.M., de Hingh, I.H.J.T., Karsten, T.M., Van der Kolk, M.B., Liem, M.S.L., Loosveld, O.J.L., Patijn, G.A., van Santvoort, H.C.M., J. de vos-Geelen, van der Holt, B., Homs, M.Y.V., van Tienhoven, G., Besselink, M.G., and Wilmink, H.W.
- Published
- 2023
- Full Text
- View/download PDF
7. Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
- Author
-
Wensink, G.E., Elferink, M.A., May, A.M., Mol, L., Hamers, P.A.H., Bakker, S.D., Creemers, G.J., Groot, J.W.B. de, Klerk, G.J. de, Haberkorn, B.C.M., Haringhuizen, A.W., Hoekstra, R., Hunting, J.C.B., Kerver, E.D., Mathijssen-van Stein, D., Polée, M.B., Pruijt, J.F., Ufford-Mannesse, P. Quarles van, Radema, S.A., Rietbroek, R.C., Simkens, L.H., Tanis, B.C., Huinink, D. Ten Bokkel, Tjin, A.T.M.L.R., Tromp-van Driel, C.S., Troost, M.M., Wouw, A.J. van de, Berkmortel, F. van den, Pas, A.J.M. van der, Velden, A.M. van der, Dijk, M.A van, Dodewaard-de Jong, J.M. van, Druten, E.B. van, Voorthuizen, T. van, Veldhuis, G., Verheul, H.M.W., Vestjens, H., Vincent, J.B., Kranenburg, O.W., Punt, C.J.A., Vink, G.R., Roodhart, J.M.L., Koopman, M., Wensink, G.E., Elferink, M.A., May, A.M., Mol, L., Hamers, P.A.H., Bakker, S.D., Creemers, G.J., Groot, J.W.B. de, Klerk, G.J. de, Haberkorn, B.C.M., Haringhuizen, A.W., Hoekstra, R., Hunting, J.C.B., Kerver, E.D., Mathijssen-van Stein, D., Polée, M.B., Pruijt, J.F., Ufford-Mannesse, P. Quarles van, Radema, S.A., Rietbroek, R.C., Simkens, L.H., Tanis, B.C., Huinink, D. Ten Bokkel, Tjin, A.T.M.L.R., Tromp-van Driel, C.S., Troost, M.M., Wouw, A.J. van de, Berkmortel, F. van den, Pas, A.J.M. van der, Velden, A.M. van der, Dijk, M.A van, Dodewaard-de Jong, J.M. van, Druten, E.B. van, Voorthuizen, T. van, Veldhuis, G., Verheul, H.M.W., Vestjens, H., Vincent, J.B., Kranenburg, O.W., Punt, C.J.A., Vink, G.R., Roodhart, J.M.L., and Koopman, M.
- Abstract
Contains fulltext : 230109.pdf (Publisher’s version ) (Closed access), BACKGROUND: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. METHODS: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. RESULTS: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. CONCLUSION: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.
- Published
- 2021
8. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
- Author
-
de Joode, Karlijn, primary, Dumoulin, Daphne W., additional, Tol, Jolien, additional, Westgeest, Hans M., additional, Beerepoot, Laurens V., additional, van den Berkmortel, Franchette W.P.J., additional, Mutsaers, Pim G.N.J., additional, van Diemen, Nico G.J., additional, Visser, Otto J., additional, Oomen-de Hoop, Esther, additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, Hendriks, Lizza E.L., additional, Haanen, John B.A.G., additional, de Vries, Elisabeth G.E., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, van Loenhout, C.J., additional, van der Leest, C.H., additional, Becker-Commissaris, A., additional, Borgers, J.S.W., additional, Terhegggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Klaver, Y., additional, Hamberg, A.P., additional, Libourel, E.J., additional, Strobbe, L., additional, Cloos, M., additional, Geraedts, E.J., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Nuij, V.J.A.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, Westeinde, S.C. van 't, additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, Herder, G.J.M., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Herbschleb, K.H., additional, Kastelijn, E.A., additional, Brocken, P., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, Peerdeman, A.L., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, van Geffen, W.H., additional, and Bootsma, G.P., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial
- Author
-
Mackay, T.M., Smits, F.J., Latenstein, A.E.J., Bogte, A., Bonsing, B.A., Bos, H., Bosscha, K., Brosens, L.A.A., Hol, L., Busch, O.R., Creemers, G.J., Curvers, W.L., Dulk, M den, Dieren, S. van, Driel, L. van, Festen, S., Geenen, E.J.M. van, Geest, L.G. van der, Groot, D.J.A. de, Groot, J.W.B. de, Mohammad, N. Haj, Haberkorn, B.C.M., Haver, J.T., Harst, E, Hemmink, G.J.M., Hingh, I.H. de, Hoge, C., Homs, M.Y.V., Huijgevoort, N.C. van, Jacobs, M.M.E., Kerver, E.D., Liem, M.S., Los, M., Lubbinge, H., Luelmo, S.A.C., Meijer, V.E. de, Mekenkamp, L., Molenaar, I.Q., Oijen, M.G. van, Patijn, G.A., Quispel, R., Rijssen, L.B. van, Romkens, T.E.H., Santvoort, H.C. van, Schreinemakers, J.M.J., Schut, H., Seerden, T., Stommel, M.W., Tije, A.J. Ten, Venneman, N.G., Verdonk, R.C., Verheij, J., Vilsteren, F.G.I. van, Vos-Geelen, J. de, Vulink, A., Wientjes, C., Wit, F., Wessels, F.J., Zonderhuis, B., Werkhoven, C.H. van, Hooft, Jeanin E. van, Eijck, C.H. van, Wilmink, J.W., Laarhoven, H.W. van, Besselink, M.G.H., Mackay, T.M., Smits, F.J., Latenstein, A.E.J., Bogte, A., Bonsing, B.A., Bos, H., Bosscha, K., Brosens, L.A.A., Hol, L., Busch, O.R., Creemers, G.J., Curvers, W.L., Dulk, M den, Dieren, S. van, Driel, L. van, Festen, S., Geenen, E.J.M. van, Geest, L.G. van der, Groot, D.J.A. de, Groot, J.W.B. de, Mohammad, N. Haj, Haberkorn, B.C.M., Haver, J.T., Harst, E, Hemmink, G.J.M., Hingh, I.H. de, Hoge, C., Homs, M.Y.V., Huijgevoort, N.C. van, Jacobs, M.M.E., Kerver, E.D., Liem, M.S., Los, M., Lubbinge, H., Luelmo, S.A.C., Meijer, V.E. de, Mekenkamp, L., Molenaar, I.Q., Oijen, M.G. van, Patijn, G.A., Quispel, R., Rijssen, L.B. van, Romkens, T.E.H., Santvoort, H.C. van, Schreinemakers, J.M.J., Schut, H., Seerden, T., Stommel, M.W., Tije, A.J. Ten, Venneman, N.G., Verdonk, R.C., Verheij, J., Vilsteren, F.G.I. van, Vos-Geelen, J. de, Vulink, A., Wientjes, C., Wit, F., Wessels, F.J., Zonderhuis, B., Werkhoven, C.H. van, Hooft, Jeanin E. van, Eijck, C.H. van, Wilmink, J.W., Laarhoven, H.W. van, and Besselink, M.G.H.
- Abstract
Contains fulltext : 225263.pdf (publisher's version ) (Open Access), BACKGROUND: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal. We hypothesized that a nationwide program to enhance implementation of these best practices in pancreatic cancer care would improve survival and quality of life. METHODS/DESIGN: PACAP-1 is a nationwide multicenter stepped-wedge cluster randomized controlled superiority trial. In a per-center stepwise and randomized manner, best practices in pancreatic cancer care regarding the use of (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents are implemented in all 17 Dutch pancreatic centers and their regional referral networks during a 6-week initiation period. Per pancreatic center, one multidisciplinary team functions as reference for the other centers in the network. Key best practices were identified from the literature, 3 years of data from existing nationwide registries within the Dutch Pancreatic Cancer Project (PACAP), and national expert meetings. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature, and can be executed within daily clinical practice. The implementation process includes monitoring, return visits, and provider feedback in combination with education and reminders. Patient outcomes and compliance are monitored within the PACAP registries. Primary outcome is 1-year overall survival (for all disease stages). Secondary outcomes include quality of life, 3- and 5-year overall survival, and guideline compliance. An improvement of 10% in 1-year overall survival is considered clinically relevant. A 25-month study duration was chosen, which provides 80% statistical power for a mortality reduction of 10.0% in the 17 pancreatic cancer centers, with a required sample size of 2142 patients, corresponding to a 6.6% m
- Published
- 2020
10. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
- Author
-
de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M. (Hans), Beerepoot, L.V. (Laurens), van den Berkmortel, F.W.P., Mutsaers, P.G.N.J. (Pim), van Diemen, N.G.J., Visser, O.J., Oomen-de Hoop, E., Bloemendal, H.J. (Haiko), van Laarhoven, HW, Hendriks, L.E.L., Haanen, J.B. (John), de Vries, E.G., Dingemans, A.M.A., van der Veldt, A.A.M., Loenhout, C.J. (Keetie) van, van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, BE, van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P. (Paul), Libourel, E.J. (Eduard), Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C. (Jan), Heller, R., de Groot, J.W.H., Stigt, JA, Nuij, V.J.A.A. (Veerle), Pitz, C.C.M., Slingerland, M. (Marije), Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C.V., Aarts, M.J.B. (Maureen), van Putten, J.W.G., Youssef, M., Cirkel, G.A. (Geert), Herder, G.J., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H., Claessens, N.J.M., Faber, LM, Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H. (Karin), Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M. (Karin), van Lindert, A.S.R., de Wouw, A.J.V., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P. (G.), de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M. (Hans), Beerepoot, L.V. (Laurens), van den Berkmortel, F.W.P., Mutsaers, P.G.N.J. (Pim), van Diemen, N.G.J., Visser, O.J., Oomen-de Hoop, E., Bloemendal, H.J. (Haiko), van Laarhoven, HW, Hendriks, L.E.L., Haanen, J.B. (John), de Vries, E.G., Dingemans, A.M.A., van der Veldt, A.A.M., Loenhout, C.J. (Keetie) van, van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, BE, van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P. (Paul), Libourel, E.J. (Eduard), Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C. (Jan), Heller, R., de Groot, J.W.H., Stigt, JA, Nuij, V.J.A.A. (Veerle), Pitz, C.C.M., Slingerland, M. (Marije), Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C.V., Aarts, M.J.B. (Maureen), van Putten, J.W.G., Youssef, M., Cirkel, G.A. (Geert), Herder, G.J., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H., Claessens, N.J.M., Faber, LM, Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H. (Karin), Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M. (Karin), van Lindert, A.S.R., de Wouw, A.J.V., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., and Bootsma, G.P. (G.)
- Abstract
Aim of the study: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients’ characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age 65 years (p < 0.001), male gender (p Z 0.035), prior or other malignancy (p Z 0.045) and active diagnosis of haematological malignancy (p Z 0.046) or lung cancer (p Z 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (65 years). Conclusion: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered
- Published
- 2020
- Full Text
- View/download PDF
11. Effect of prednisone on docetaxel pharmacokinetics in metastatic prostate cancer: A randomized drug-drug interaction study
- Author
-
Belderbos, B.P.S.I., primary, Hussaarts, K.G.A.M., additional, van Harten, L., additional, Oomen-De Hoop, E., additional, de Bruijn, P., additional, Hamberg, P., additional, van Alphen, R.J., additional, Haberkorn, B.C.M., additional, van Soest, R.J., additional, de Wit, R., additional, and Mathijssen, R.H.J., additional
- Published
- 2018
- Full Text
- View/download PDF
12. 855P - Effect of prednisone on docetaxel pharmacokinetics in metastatic prostate cancer: A randomized drug-drug interaction study
- Author
-
Belderbos, B.P.S.I., Hussaarts, K.G.A.M., van Harten, L., Oomen-De Hoop, E., de Bruijn, P., Hamberg, P., van Alphen, R.J., Haberkorn, B.C.M., van Soest, R.J., de Wit, R., and Mathijssen, R.H.J.
- Published
- 2018
- Full Text
- View/download PDF
13. Improving diagnosis of adult-type hypolactasia in patients with abdominal complaints
- Author
-
Haberkorn, B.C.M., Ermens, A.A.M., Koeken, A., Cobbaert, C.M., and Guldener, C. van
- Subjects
lactose intolerance ,single nucleotide polymorphism ,breath test ,lactase - Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.